BiotechTube
Home/Pipeline/SL-425

SL-425

Inflammatory Bowel Disease (IBD)

Phase 1Active

Key Facts

Indication
Inflammatory Bowel Disease (IBD)
Phase
Phase 1
Status
Active
Company
Shattuck Labs

About Shattuck Labs

Shattuck Labs is a clinical-stage biotech with a mission to establish DR3 blockade as a new standard of care in inflammatory and immune-mediated diseases. The company has rapidly advanced its lead asset, SL-325, into Phase 2 development for IBD, leveraging a differentiated receptor-blocking strategy to potentially overcome limitations of existing TL1A-targeting therapies. Its strategy hinges on demonstrating best-in-class remission rates and a favorable immunogenicity profile to capture significant market share in the competitive IBD landscape.

View full company profile

Therapeutic Areas

Inflammatory Bowel DiseaseAutoimmune Diseases

Other Inflammatory Bowel Disease (IBD) Drugs

DrugCompanyPhase
HBM2001Harbour BioMedDiscovery
Metabolite Delivery Platform (Therapeutic Programs)ClostraBioPre-clinical
ABO21009AboleIIs PharmaPhase 1
GlyHealth BiomarkersAvennaPre-clinical/Validation
GTI-850GSNO TherapeuticsPre-clinical
CK-0045Cytoki PharmaPre-clinical/Research
MV-010MV BioTherapeuticsPreclinical
NM81Numab InnovationPre-clinical
LIAISON® CalprotectinDiaSorinCommercial
SL-325Shattuck LabsPhase 2
VE202PureTech HealthPhase 2